Nozaki M, Hashimoto K, Inoue Y, Sano M, Nakano H
Department of Gynecology and Obstetrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Nihon Sanka Fujinka Gakkai Zasshi. 1996 Feb;48(2):83-8.
To assess the effect of estriol (E3) on bone loss in Japanese postmenopausal women, twenty-five women within 10 years after menopause received 2 mg/day of E3 and 2 g/day of calcium lactate (Ca) daily (n = 17; Group-E3 + Ca) or 2 g/day of Ca daily (n = 8; Group-Ca) for one year. Bone mineral density (BMD) at the lumbar spine L2 - L4 was evaluated by dual energy X-ray absorptiometry (DXA). In Group-Ca, BMD was significantly reduced (p < 0.05 vs. pretreatment) at the end of the study period. In contrast, in Group-E3 + Ca, the mean percent increase in BMD was 1.66%, which was significantly higher than that of Group-Ca (-3.08%; p < 0.001). As for the biochemical markers of bone metabolism, bone specific alkaline phosphatase (ALPIII) reflecting bone formation, and pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) reflecting bone resorption, were significantly decreased (p < 0.001) in Group-E3 + Ca after six months of treatment. These data indicate that the acceleration of bone turnover usually observed after menopause was prevented by treatment with E3. As to the side effects of E3, only one of the 17 patients experienced a slight increase in vaginal discharge, but no other side effects were observed. Accordingly, reasonable compliance can be expected among postmenopausal women treated with E3 to prevent bone loss.
为评估雌三醇（E3）对日本绝经后女性骨质流失的影响，25名绝经后10年内的女性每天接受2毫克E3和2克乳酸钙（Ca）（n = 17；E3 + Ca组）或每天仅接受2克Ca（n = 8；Ca组），为期一年。采用双能X线吸收法（DXA）评估腰椎L2 - L4的骨密度（BMD）。在Ca组中，研究期末BMD显著降低（与治疗前相比，p < 0.05）。相比之下，在E3 + Ca组中，BMD的平均增加百分比为1.66%，显著高于Ca组（-3.08%；p < 0.001）。至于骨代谢的生化标志物，反映骨形成的骨特异性碱性磷酸酶（ALPIII）以及反映骨吸收的吡啶啉（Pyr）和脱氧吡啶啉（D - Pyr），在E3 + Ca组治疗6个月后显著降低（p < 0.001）。这些数据表明，绝经后通常观察到的骨转换加速通过E3治疗得以预防。至于E3的副作用，17名患者中只有1名出现白带略有增加，但未观察到其他副作用。因此，对于接受E3治疗以预防骨质流失的绝经后女性，可以预期其有合理的依从性。
